Skip to content

Comparing Ayurvedic Haridradi siddha milk eye wash and anu taila nasal drop with Standard Treatments for Dry Eyes Caused by Meibomian Gland Dysfunction A Randomized Clinical Trial

Evaluation of comparative efficacy of Haridradi Siddha Paya Parishek with Anu Tail Marsha Nasya versus Standard Treatment Protocol in the Management of Meibomian Gland Dysfunction (Shushkakshipaka): Randomized Clinical Trial - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/092687
Enrollment
54
Registered
2025-08-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H028- Other specified disorders of eyelid

Interventions

None listed

Sponsors

Dr Prajwal Dilip Piprewar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of age 18 years to 60 years will be selected irrespective of their gender caste religion socio-economic or educational status Patient suffering from Dry Eye Syndrome Patients with Myopia and Hypermetropia will be selected Patients with anatomically normal ocular structures will be selected Patients who are ready to accept the treatment will be selected Written Consent

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Improvement in clinical symptoms of Shushkakshipaka dryness irritation itching photophobia Tear Film Break-Up Time Timepoint: Day 0 (Baseline) Day 15 (Mid-treatment Follow-up) Day 30 (Final Assessment)

Secondary

MeasureTime frame
improvement in Meibomian Gland Expression Test Schirmer s Test Meibography Microscopic Swab CultureTimepoint: 4 weeks

Countries

India

Contacts

Public ContactDr Roshana Rathi

Mahatma Gandhi Ayurvedic College and Research Centre Salod Wardha

roshana.bhutada@dmiher.edu.in8766866422

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026